特纳比阿地在抑制拉米变异株方面好

zasxz

Embargoed for Release: October 24, 2003

The treatment of chronic hepatitis B with Lamivudine is frequently  impaired
by the development of resistance of HBV against Lamivudine leading to
disease progression. According to Dr. van Bommel,

"Effective drugs for patients with lamivudine resistant hepatitis B
infections are urgently needed."

Adefovir has recently been approved for the treatment of Lamivudine
resistant hepatitis B, but this prospective study of HBV kinetics suggests
Tenofovir, which is used in the treatment of HIV infection, is more potent
than Adefovir.
Fifty five patients with hepatitis B who developed resistance to
Lamivudine  after being treated with it for at least 24 months were studied.
Of those  patients 19 were treated with Adefovir and thirty six were treated
with  Tenofovir for at least three months.
Three variables were measured during the study: HBV DNA, ALT, and
creatinine.
a.. Hepatitis B viremia declined more rapidly in patients treated with
Tenofovir than in patients treated with Adefovir. When measured at the
6-month point, HBV became negative in 69% of patients treated with
Tenofovir, compared with 37% of patients treated with Adefovir.  b.. ALT
decline was significantly faster in patients treated with  Tenofovir than in
patients treated with Adefovir.  c.. Creatinine levels remained in normal
ranges for and no significant  side effects were observed in both groups.
The researchers conclude that Tenofovir seems to be superior to Adefovir
in  suppressing Lamivudine-resistant mutants.
AASLD is the leading medical organization for advancing the science and
practice of hepatology. Founded by physicians in 1950, AASLD's vision is
to  prevent and cure liver diseases. This year's Liver Meeting, held in
Boston,  Massachusetts, from October 29 to November 2, will bring more than
5,500  hepatologist and hepatology professionals from all around the world.
A press room will be available from October 30 at the annual meeting. For
copies of abstracts and press releases, or to arrange for pre-conference
research interviews contact Gregory Bologna at 703-299-9766. To
pre-register, call Lynn Price at 703-299-9766.

[此贴子已经被作者于2004-10-26 16:07:28编辑过]

zasxz

拉米变异后的有效药物急缺 October 24, 2003 阿地福韦最近在拉米耐药方面被认为是有效的，但是对HBV动力学研究表明，特纳福韦 Tenofovir 原先是治疗 HIV 感染的，可能更加有效。 55名拉米24月治疗后变异患者接受了研究。 其中19名用阿地治疗，36名用特纳治疗3月。三种变量被经常检测 HBV DNA, ALT, 和肌酐

a.. Hepatitis B 病毒血症下降速度方面，特纳快于阿地。6个月时，69％的特纳治疗病人HBV显阴性，阿地中只有39％显阴性。

b.. ALT 下降速度，特纳显著快于阿地。

c.. 肌酐方面，两组均没有发生明显副作用。

研究人员评估特纳比阿地在抑制拉米变异株方面好。